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Background: Hereditary pancreatitis-associated mutations alter regulation of trypsinogen activation by chymotrypsin C.
Results: Activation of mouse trypsinogens T8 and T9 is inhibited by chymotrypsin C-mediated cleavage of the autolysis loop.
Conclusion: Chymotrypsin C regulates activation of human and mouse trypsinogens by different mechanisms.
Significance: Introduction of human pancreatitis-associated mutations into mouse trypsinogens will not recapitulate the
pathogenic biochemical effects.
Chymotrypsin C (CTRC) is a proteolytic regulator of tryp-
sinogen autoactivation in humans. CTRC cleavage of the
trypsinogen activation peptide stimulates autoactivation,
whereas cleavage of the calcium binding loop promotes trypsin-
ogen degradation. Trypsinogenmutations that alter these regu-
latory cleavages lead to increased intrapancreatic trypsinogen
activation and cause hereditary pancreatitis. The aim of this
study was to characterize the regulation of autoactivation of
mouse trypsinogens by mouse Ctrc. We found that the mouse
pancreas expresses four trypsinogen isoforms to high levels, T7,
T8, T9, and T20. Only the T7 activation peptide was cleaved by
mouse Ctrc, causing negligible stimulation of autoactivation.
Surprisingly, mouse Ctrc poorly cleaved the calcium binding
loop in all mouse trypsinogens. In contrast, mouse Ctrc readily
cleaved thePhe-150–Gly-151peptide bond in the autolysis loop
ofT8 andT9 and inhibited autoactivation.Mouse chymotrypsin
B also cleaved the same peptide bond but was 7-fold slower. T7
was less sensitive to chymotryptic regulation, which involved
slow cleavage of the Leu-149–Ser-150 peptide bond in the
autolysis loop.Modeling indicated steric proximity of the autol-
ysis loop and the activation peptide in trypsinogen, suggesting
the cleaved autolysis loopmay directly interfere with activation.
Weconclude that autoactivationofmouse trypsinogens is under
the control of mouse Ctrc with some notable differences from
the human situation. Thus, cleavage of the trypsinogen activa-
tion peptide or the calciumbinding loop byCtrc is unimportant.
Instead, inhibition of autoactivation via cleavage of the autolysis
loop is the dominant mechanism that canmitigate intrapancre-
atic trypsinogen activation.
Hereditary chronic pancreatitis is a human genetic disorder
caused by heterozygous mutations in the serine protease 1
(PRSS1) gene, which codes for the digestive proenzyme cationic
trypsinogen (1). High penetrance trypsinogen mutations such
as p.N29I and p.R122H are associated with an autosomal dom-
inant inheritance pattern, whereas mutations with lower pen-
etrance, exemplified by p.A16V, may be found not only in
hereditary but also in sporadic cases with no family history (2).
The disease mechanism involves increased autoactivation of
mutant trypsinogens within the pancreas due to altered regula-
tion by chymotrypsin C (CTRC)2 (3). Autoactivation of human
trypsinogens is proteolytically regulated by CTRC that cleaves
cationic trypsinogen at twodistinct regulatory sites. Cleavage of
the Phe-18–Asp-19 peptide bond in the activation peptide
results in a shorter activation peptide and increased autoacti-
vation (4). This cleavage is stimulated by pancreatitis-associ-
ated mutations p.N29I and p.A16V (3, 4). Cleavage of the Leu-
81–Glu-82 peptide bond in the calcium binding loop, together
with the trypsin-mediated autolytic cleavage of the Arg-122–
Val-123 peptide bond, results in rapid degradation and inacti-
vation of cationic trypsinogen (5). Mutations p.N29I and
p.R122H hamper CTRC-mediated degradation and thereby
increase trypsinogen autoactivation (3).
Despite the significant progress in understanding the mech-
anism of trypsinogen mutations at the biochemical level, ani-
mal models that recapitulate the human disease both pheno-
typically and mechanistically remain unavailable. Transgenic
mice carrying the coding DNA for human cationic trypsinogen
with the p.R122H mutation did not develop spontaneous pan-
creatitis, although small differences in the pathological
responseswere notedwhen pancreatitis was artificially induced
(6). In contrast, when mice were made transgenic with the
p.R122Hmutation introduced intomouse trypsinogen isoform
T8 (see Table 1), the resulting animals developed acute and
eventually chronic pancreatitis (7). Unfortunately, this remark-
able model has never been made available to the pancreas
research community for independent replication nor have
there been any follow-up studies published by the original
authors since 2006. It thus remains unclear whether the
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observed phenotypewas related to the expression of themutant
trypsinogen. Nonetheless, this study raises the question
whether the biochemical effects of the p.R122H mutation are
similar in the context of mouse and human trypsinogens and
whether we can utilize mouse trypsinogens to model the
human condition.
Considering the widespread use of mice in experimental
studies of the pancreas, it is surprising how little is known about
mouse trypsinogens. Watanabe and Ogasawara (8) reported
the purification of three trypsinogen isoforms from the mouse
pancreas. Stevenson et al. (9) cloned a trypsinogen cDNA, cor-
responding to isoform T20, from the pancreas and demon-
strated that the mouse genome contained multiple different
trypsinogen genes. This was later confirmed by Hood and co-
workers in 1997 (10) who sequenced the mouse T cell receptor
 locus on chromosome 6 and identified 20 trypsinogen genes
organized in two groups, one containing genes T1–T7 and the
other containing genes T8–T20 (Table 1). Eleven of the 20
genes are potentially functional (Table 1 and Fig. 1), whereas
the other nine genes are pseudogenes or relic genes. Ohmura et
al. (11) cloned the cDNA for isoformT9 from sperm acrosome.
It remains unknown, however, which isoforms of the 11 poten-
tially functional trypsinogen genes are expressed at the protein
level in the mouse pancreas. More recently, genetic deletion of
T7 indicated that this isoform may contribute as much as 60%
of pancreatic trypsinogens (12, 13). The authors also found that
despite the presence of other trypsinogen isoforms, mice defi-
cient in T7 did not respond to secretagogue hyperstimulation
with the characteristic intra-acinar cell trypsinogen activation,
an early event in acute pancreatitis. These new findings suggest
that the differentmouse trypsinogen isoforms vary in their acti-
vation kinetics and highlight the need for their comparative
biochemical characterization. Therefore, in this study, we iden-
tified the major trypsinogen isoforms in the mouse pancreas,
expressed these recombinantly, and studied their autoactiva-
tion and regulation by mouse Ctrc.
EXPERIMENTAL PROCEDURES
Nomenclature—Amino acid residues are numbered start-
ing with the initiator methionine of the primary translation
product, according to the recommendations of the Human
GenomeVariation Society. Note that because of an extra Asp
residue (Asp-23) in the activation peptide of T7, amino acid
numbering in this isoform is shifted by one relative to human
and other mouse trypsinogens. Autolysis loop refers to the
flexible region between residues 146 and 154 in trypsinogen
(Fig. 1).
Plasmid Construction and Mutagenesis—Construction of
the pTrapT7-intein-Hu1 and pcDNA3.1()-CTRB2 expres-
sion plasmids harboring the coding sequence for human cat-
ionic trypsinogen (Hu1) and human chymotrypsinogen B2
(CTRB2)was reported previously (5, 14).Mutation p.S150Fwas
introduced into human cationic trypsinogen using overlap-ex-
tension PCR mutagenesis. Expression plasmids for mouse
trypsinogens were created in the pTrapT7 plasmid previously
designed for bacterial expression of human trypsinogens (15,
16). The coding DNA was PCR-amplified from commercial
IMAGE clones and cloned into pTrapT7 using NcoI and SalI
restriction sites. In all constructs, the N-terminal secretory sig-
nal peptide was replaced with a Met-Ala sequence. In T20, the
stop codonwas changed fromamber (TAG) to ochre (TAA). T7
was amplified from IMAGE clone 30306963 (GenBankTM
accession BC061093.1) using T7 NcoI sense (5-AAA TTT
CCA TGG CTC TCC CCC TGG ATG ATG ATG ATG-3,
where the NcoI site is underlined) and T7 SalI antisense
(5-AAA TTT GTC GAC TTA GTT GGC AGC GAT GGT
CTGCTG-3, where the SalI site is underlined) primers. T8was
amplified from IMAGEclone 30306436 (GenBankTMaccession
BC061135.1) using T8 NcoI sense (5-AAA TTT CCA TGG
CTTTCCCTGTGGATGATGATGACA-3, where theNcoI
site is underlined) and T8 SalI antisense (5-AAA TTT GTC
GACTTAGTTTGCAGCAATGGTGTTTTG-3, where the
TABLE 1
Trypsinogen genes in the mouse genome
Table is based on the 1997 GenBankTM submissions AE000663.1, AE000664.1, and AE000665.1, which first reported the genomic sequence of the mouse T cell receptor 
locus. The original annotation described genes T2 and T14 as relic genes based on the absence of exon 1. The more recent annotation to the mouse genome identified the
first exons for both genes, and we re-classified these as pseudogenes.
Gene Function Notes
T1 Pseudogene Exons give in-frame translation; product may serve unknown function
Also known as protease, serine 58 (Prss58), GenBankTM NM_175020.3
T2 Pseudogene Exons give in-frame translation; product may serve unknown function
T3 Pseudogene A single nucleotide deletion in exon 2 leads to a frameshift
T4 Functional
T5 Functional
T6 Relic This gene has only exons 2 and 3
T7 Functional
T8 Functional Also known as trypsin4 (Try 4), GenBankTM NM_011646.5
T9 Functional Also known as trypsin5 (Try 5) GenBankTM NM_001003405.4
Also known as TESP4, GenBankTM AB017031.1
T10 Functional
T11 Functional Also known as protease, serine,3 (Prss3), GenBankTM NM_011645.2
T12 Functional
T13 Relic This gene has only exons 3 and 5
T14 Pseudogene This gene has a defective splice site after exon 2
T15 Functional
T16 Functional Also known as protease, serine,1 (Prss1), GenBankTM NM_053243.2
T17 Relic This gene is missing exons 1 and 2
T18 Relic This gene is missing exons 1 and 2
T19 Relic This gene has only exon 3
T20 Functional Also known as protease, serine,2 (Prss2), GenBankTM NM_009430.2
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SalI site is underlined) primers. T9 was amplified from IMAGE
clone 6433372 (GenBankTM accession CF581321.1) using T8
NcoI sense and T9 SalI antisense (5-AAA TTT GTC GAC
TTAGTT TGCGGCAATGGTGTC CTG-3, where the SalI
site is underlined) primers. T20 was amplified from IMAGE
clone 6433384 (GenBankTM accession CF581305.1) using T20
NcoI sense (5-AAA TTT CCA TGG CTT TCC CTG TGG
ATG ATG ATG ACA-3, where the NcoI site is underlined)
and T20 SalI antisense (5-AAA TTT GTC GAC TTA GTT
GTC AGC AAT TGT GTT CTG-3, where the SalI site is
underlined) primers. Mutations p.L82A, p.R123H, and
p.L149A in T7 and p.R122H in T8 were created by overlap
extension PCR and cloned into the pTrapT7 plasmid.
Expression plasmids for mouse chymotrypsinogens carrying
a His10 affinity tag were created in the pcDNA3.1() plasmid.
The coding DNA for mouse chymotrypsinogen C (Ctrc) was
PCR-amplified from a cDNA preparation from CD-1 mouse
pancreas, using mouse CTRC XhoI sense (5-AAA TTT CTC
GAG ACC TGA ACC ATG TTG GGA ATT ACA GTC-3,
where the XhoI site is underlined) and mouse CTRC EcoRI
antisense (5-AAATTTGAATTCGGCGTCGAGACTTCT
GGA ACC GTC TCT-3, where the EcoRI site is underlined)
primers and cloned into pcDNA3.1() using XhoI and EcoRI.
A His10 affinity tag was added to the C terminus using gene
synthesis (GenScript, Piscataway, NJ) and the XcmI and
EcoRI sites. In this synthetic construct Leu-268 was deleted
to prevent autolytic cleavage of the His tag. The coding DNA
for mouse chymotrypsinogen B (Ctrb, GenBankTM accession
NM_025583.2) with a C-terminal His10 tag was custom-syn-
thesized (GenScript) and cloned into pcDNA3.1() using
XhoI and BamHI.
Purification and Identification of Trypsinogens from CD-1
Mouse Pancreas—Pancreata (2 to 3) were homogenized in 10
ml of 20 mM Na-HEPES (pH 7.4) buffer, briefly sonicated, and
centrifuged at 13,500 rpm for 10min, and4ml of supernatant
was loaded onto a 2-ml ecotin column. Ecotin is a pan-serine
protease inhibitor from Escherichia coli, which can bind the
inactive zymogen forms of pancreatic serine proteases (17, 18).
The ecotin column was washed with 20 mM Tris-HCl (pH 8.0),
0.2 MNaCl, and trypsinogens were eluted with 50mMHCl. The
flow-through contained no trypsinogen, as judged by the
lack of trypsin activity after incubation with enteropepti-
dase. The ecotin-eluate contained all trypsinogen isoforms
and low levels of chymotrypsinogen and proelastase. Four ml
of eluate was loaded onto a 2-ml Mono S column equili-
brated with 20 mM sodium acetate (pH 5.0), and trypsino-
gens were eluted with a 0–0.5MMNaCl gradient at 1 ml/min
flow rate (Fig. 2A). The eluted proteins were separated by
SDS-PAGE and transferred to a PVDF membrane, and indi-
vidual bands were subjected to N-terminal protein sequenc-
ing by Edman degradation (Midwest Analytical, St. Louis,
MO). Peaks corresponding to T8, T9, and T20 were also
subjected to in-gel digestion followed by LC-MS/MS mass
spectrometry (ProtTech, Phoenixville, PA). Relative abun-
dance of trypsinogen isoforms was calculated from the peak
areas corrected for the ultraviolet extinction coefficient dif-
ferences. The T9-T8 peaks were also corrected for Ctrb con-
tamination, which was determined from the relative trypsin
and chymotrypsin activities after activation with enteropep-
tidase. Because of the poor separation of T8 and T9, these
two isoforms were calculated as one.
Identification of Trypsinogens fromNMRIMouse Pancreas by
Two-dimensional PAGE and Mass Spectrometry—Pancreata
were homogenized in a Potter homogenizer at 2,500 rpm in
ice-cold homogenization buffer (HS buffer, 250mM sucrose, 10
mM citric acid (pH 6.0), 0.5 mM EGTA, 0.1 mM MgSO4) with
Complete mini protease inhibitor mixture (Roche Applied Sci-
ence). The homogenate was centrifuged for 5 min at 500  g,
and the post-nuclear supernatant was centrifuged at 1,300 g
for 15 min at 4 °C. This zymogen granule-enriched pellet was
washedwithHS buffer and dissolved in sample buffer (5 M urea,
2 M thiourea, 2 M CHAPS, 2% ASB-14, 0.05% SB3–10) with
Complete mini protease inhibitor mixture and stored in ali-
quots at80 °C.
Immobilized pH gradient (IPG) strips (pH 3–10, 13 cm)were
rehydrated overnight in sample buffer containing 65 mM (10
mg/ml) dithiothreitol (DTT), 2% IPG buffer, and 0.01% Serva
blue. The zymogen granule-enriched pancreatic extract dis-
solved in sample buffer (50–100g) was supplementedwith 65
mM (10 mg/ml) DTT, 2% IPG buffer, 0.01% Serva blue and
cup-loaded at the anode end of the strips. Isoelectric focusing
was performed undermineral oil at 3,500 Vwith a current limit
of 50Aper strip up to 8,000 total volt hours using an IPGphor
unit (Amersham Biosciences). Strips were subsequently incu-
bated in equilibration buffer (0.5 M Tris-HCl (pH 8.8), 6 M urea,
2%SDS, 30%glycerol) containing 50mMDTT followed by incu-
bation in 0.3 M acrylamide, for 15min each. For electrophoresis
in the second dimension, the IPG strips were applied onto a
10.5% SDS-polyacrylamide gel, and proteins were separated
according to Schaegger and van Jagow (19). Gels were stained
with silver nitrate by a modified method of Blum et al. (20). For
estimation of relative protein content of trypsinogen spots, gels
were further stainedwith Serva blue, according toNeuhoff et al.
(21). Gel images were analyzed, and spot intensities were quan-
titated with the ImageMaster 2D Elute version 3.10 software
(Amersham Biosciences). Protein spots of interest were
excised, de-stained, and digested in-gel with sequencing grade
bovine trypsin (RocheApplied Science, 12.5 ng/l) overnight at
37 °C. Peptides were extracted from gel slices, andmass spectra
were analyzed usingMALDI-TOFReflex IIImass spectrometer
machine (Bruker Daltonics, Germany) in linear mode with
external calibration. Peptide fingerprint data analysis was per-
formed using the web-based ProFound database with a mass
tolerance of 250 ppm.
Expression and Purification of Trypsinogens—Human cati-
onic trypsinogen was expressed in the aminopeptidase P-defi-
cient LG-3 E. coli strain as fusions with a self-splicing mini-
intein, as described previously (14, 22). Mouse trypsinogens
were expressed in E. coli BL21(DE3), as described for human
trypsinogens previously (15, 16). Isolation of cytoplasmic
inclusion bodies, in vitro refolding, and purification with
ecotin affinity chromatography were performed according
to published protocols (14–16, 18, 22). The preparations
were more than 90% pure, as judged by SDS-PAGE and Coo-
massie Blue staining. Concentrations of trypsinogen solu-
tions were calculated from their UV absorbance at 280 nm
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using the following extinction coefficients: 37,525 M1cm1
(human cationic trypsinogen), 39,140 M1cm1 (mouse T7),
34,670 M1cm1 (mouse T8 and T9), and 43,150 M1cm1
(mouse T20).
Expression and Purification of Chymotrypsinogens—Human
CTRB2 and mouse Ctrb and Ctrc carrying His10 affinity tags
were expressed in transiently transfected HEK 293T cells and
purified from 450ml of conditionedmediumusing nickel affin-
ity chromatography as reported previously (3, 23). Aliquots (75
l) of the eluted 5-ml fractions were analyzed by 15% SDS-
PAGE and Coomassie Blue staining, and peak fractions with
90% purity were pooled and dialyzed for 72 h against three
changes of 1 liter of 0.1 M Tris-HCl (pH 8.0) buffer containing
150 mM NaCl. The dialyzed chymotrypsinogen solutions were
concentrated using a Vivaspin 20 concentrator (10-kDamolec-
ular mass cutoff). Chymotrypsinogens were activated with
trypsin, and active chymotrypsin concentrations were deter-
mined by active site titration with ecotin, as described previ-
ously (24).
Trypsinogen Autoactivation—Trypsinogen at 2 M concen-
tration was incubated in the absence or presence of 25 nM chy-
motrypsin, as indicated, and 10 nM initial trypsin in 0.1 M Tris-
HCl (pH 8.0), 1 or 10 mM CaCl2, and 0.05% Tween 20 (final
concentrations) at 37 °C. At given times, 1.5-l aliquots were
withdrawn and mixed with 48.5 l of assay buffer containing
0.1 M Tris-HCl (pH 8.0), 1 mM CaCl2, and 0.05% Tween 20.
Trypsin activity was measured by adding 150 l of 200 M
N-CBZ-Gly-Pro-Arg-p-nitroanilide substrate dissolved in
assay buffer and following the release of the yellow p-nitroani-
line at 405 nm in a SpectraMax plus384 microplate reader
(Molecular Devices, Sunnyvale, CA) for 1 min. Reaction rates
were calculated from fits to the initial linear portions of the
curves.
TrypsinogenActivationwith Enteropeptidase—Todetermine
the maximal trypsin activity attainable after full activation, 2
M trypsinogen was incubated in 0.1 M Tris-HCl (pH 8.0), 10
mM CaCl2, and 0.05% Tween 20 (final concentrations) at 37 °C
with 140 ng/ml final concentration of human enteropeptidase
(R&D Systems, Minneapolis, MN) for 1 h, and trypsin activity
was measured as described above. This activity was designated
as 100%, and trypsin activity measured in autoactivation exper-
iments was expressed relative to this value. The 100% values
corresponded to 500 (T7), 400 (T8), 400 (T9), and 300 (T20)
milli-OD/min readings.
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Hu1  MNPLLILTFVAAALA-APFDDDDKIVGGYNCEENSVPYQVSLNSGY-HFCGGSLINEQWVVSAGHCYKSRIQVRLGEHNIEVLEGNEQ 
T4   MKIITFFTFLGAAVA-LPANSDDKIVGGYTCPKHSVPYQVSLNDGISHQCGGSLISDQWVLSAAHCYKRRLQVRLGEHNIDVLEGGEQ 
T5   MKIIFFFTFLGAAVA-LPANSDDKIVGGYTCPKHSVPYQVSLNDGISHQCGGSLINDQWVLSAAHCYKRRLQVRLGEHNIDVLEGGEQ 
T7   MKTLIFLAFLGAAVALPLDDDDDKIVGGYTCQRNALPYQVSLNSGY-HFCGGSLINSQWVVSAAHCYKSRIQVRLGEHNIDALEGGEQ 
T8   MRALLFLALVGAAVA-FPVDDDDKIVGGYTCRENSVPYQVSLNSGY-HFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLEGNEQ 
T9   MNSLLFLALVGAAVA-FPVDDDDKIVGGYTCRENSIPYQVSLNSGY-HFCGGSLINDQWVVSAAHCYKTRIQVRLGEHNINVLEGNEQ 
T10  MSTLLFLALVGAAVA-FPVDDDDKIVGGYTCRENSVPYQVSLNSGY-HFCGGSLINDQWVVSAAHCYKSRIQVRLGEHNINVLEGNEQ 
T11  MNALLILALVGAAVA-FPVDDDDKIVGGYTCQENSVPYQVSLNSGY-HFCGGSLINDQWVVSAAHCYKTRIQVRLGEHNINVLEGNEQ 
T12  MSALLFLALVGAAVA--FPVDDDKIVGGYTCRENSVPYQVSLNSGY-HFCGGSLINDQWVVSAAHCYKTRIQVRLGEHNIKVLEGNEQ 
T15  MNAFLILALVGAAVA-FPVDDDDKIVGGYTCQENSVPYQVSLNSGY-HFCGGSLINDQWVVSAAHCYKTRIQVRLGEHNINVLEGNEQ 
T16  MSALLFLALVGAAVA-FPVDDDDKIVGGYTCRENSVPYQVSLNSGY-HFCGGSLINDQWVVSAAHCYKTRIQVRLGEHNINVLEGNEQ 
T20  MSALLILALVGAAVA-FPVDDDDKIVGGYTCRESSVPYQVSLNAGY-HFCGGSLINDQWVVSAAHCYKYRIQVRLGEHNINVLEGNEQ 
Hu1  FINAAKIIRHPQYDRKTLNNDIMLIKLSSRAVINARVSTISLPTAPPATGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEAS 
T4   FIDAEKIIRHPDYNKDTVDNDIMLIKLKSPAILNSQVSTVSLPRSCASTNAQCLVSGWGNTVSIGGKYPALLQCLEAPVLSASSCKKS 
T5   FIDAEKIIRHPDYNKDTVDNDIMLIKLKSPAILNSQVSTVSLPRSCASTNAQCLVSGWGNTVSIGGKYPALLQCLEAPVLSASSCKKS 
T7   FIDAAKIIRHPNYNANTYNNDIMLIKLKTAATLNSRVSTVALPRSCPSAGTRCLVSGWGNTLSSGTNYPSLLQCLDAPVLSDSSCTSS 
T8   FVNSAKIIKHPNFNSRTLNNDIMLIKLASPVTLNARVATVALPSSCAPAGTQCLISGWGNTLSFGVNNPDLLQCLDAPLLPQADCEAS 
T9   FVNSAKIIKHPNFNSRTLNNDIMLIKLASPVTLNARVATVALPSSCAPAGTQCLISGWGNTLSFGVNNPDLLQCLDAPLLPQADCEAS 
T10  FIDAANIIKHPKFKKKTLDNDIMLIKLSSPVTLNARVATVALPSSCAAAGTQCLISGWGNTLSSGVNNPDLLQCLDAPLLPQADCEAS 
T11  FVNAAKIIKHPNFNRKTLNNDIMLLKLSSPVTLNARVATVALPSSCAPAGTQCLISGWGNTLSFGVSEPDLLQCLDAPLLPQADCEAS 
T12  FVNAAKIIKHPNFNRKTLNNDIMLIKLSSPVTLNARVATVALPSSCAPAGTQCLISGWGNTLSFGVSEPDLLQCLDAPLLPQADCEAS 
T15  FVNAAKIIKHPNFNRKTLNNDIMLIKLSSPVTLNARVATVALPSSCAPAGTQCLISGWGNTLSFGVSEPDLLQCLDAPLLPQADCEAS 
T16  FIDAAKIIKHPNFNRKTLNNDIMLIKLSSPVTLNARVATVALPSSCAPAGTQCLISGWGNTLSFGVSEPDLLQCLDAPLLPQADCEAS 
T20  FVDSAKIIRHPNYNSWTLDNDIMLIKLASPVTLNARVASVPLPSSCAPAGTQCLISGWVTLNARVASVPDLLQCVDAPVLPQADCEAS 
Hu1  YPGKITSNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKVYNYVKWIKNTIAANS 
T4   YPGQITSNMFCLGFLEGGKDSCDGDSGGPVVCNGEIQGIVSWGSVCAMRGKPGVYTKVCNYLSWIQETMANN- 
T5   YPGQITSNMFCLGFLEGGKDSCDGDSGGPVVCNGEIQGIVSWGSVCAMRGKPGVYTKVCNYLSWIQETMANN- 
T7   YPGKITSNMFCLGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGYGCAQRGKPGVYTKVCKYVNWIQQTIAAN- 
T8   YPGKITNNMICVGFLEGGKDSCQGDSGGPVVCNGQLQGIVSWGYGCALKDNPGVYTKVCNYVDWIQNTIAAN- 
T9   YPGKITNNMICVGFLEGGKDSCQGDSGGPVVCNGQLQGIVSWGYGCALKDNPGVYTKVCNYVDWIQDTIAAN- 
T10  YPGKITKNMICVGFLEGGKDSCQGDSGGPVVCNGQLQGIVSWGYGCAQKDNPGVYTKVCNYVDWIQNTIAAN- 
T11  YPGKITGNMVCAGFLEGGKDSCQGDSGGPVVCNRELQGIVSWGYGCALPDNPGVYTKVCNYVDWIQDTIAAN- 
T12  YPGKITGNMVCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWGYGCALADNPGVYTKVCNYVDWIQDTIAAN- 
T15  YPGKITGNMVCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWGYGCALPDNPGVYTKVCNYVDWIQDTIAAN- 
T16  YPGKITGNMVCAGFLEGGKDSCQGDSGGPVVCNGELQGIVSWGYGCALPDNPGVYTKVCNYVDWIQDTIAAN- 
T20  YPGDITNNMICVGFLEGGKDSCQGDSGGPVVCNGELQGIVSWGYGCAQPDAPGVYTKVCNYVDWIQNTIADN- 
← 8
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FIGURE1.Primary sequencealignmentofhumancationic trypsinogen (Hu1) and11potentially functionalmouse trypsinogens.Numbering startswith
the initiatormethionine.Note that due to insertions in T4, T5, andT7, thenumbering is shiftedbyoneafter the insertion sites, relative to the indicatednumbers.
Similarly, a deletion in T12 shifts numbering. Trypsin cleavage sites are highlighted in blue and chymotrypsin C cleavage sites in red. Cys residues are indicated
in green and the catalytic triad inmagenta. The original annotation predicted deletion of Arg-69 (red letter) in T4 and T5, but more recent annotations include
this residue. See text for details.
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Gel Electrophoresis—Trypsinogen samples (75l,3.8g of
protein) were precipitated with trichloroacetic acid (10% final
concentration), and the precipitate was recovered by centrifu-
gation, dissolved in 15 l of Laemmli sample buffer containing
100 mM DTT (final concentration), and heat-denatured at
95 °C for 5 min. Electrophoretic separation was performed on
15% SDS-PAGE mini gels in standard Tris-glycine buffer. Gels
were stained with Brilliant Blue R-250 and destained as
described earlier (25). Quantitation of bands was carried out
with the GelDoc XR gel documentation system and Image
Lab 3.0 software (Bio-Rad).
RESULTS
Identification of Major Trypsinogen Isoforms in the Mouse
Pancreas—To identify trypsinogen isoforms expressed at high
levels in the mouse pancreas, we used ecotin-affinity chroma-
tography to purify trypsinogens en bloc from pancreas tissue
extracts of the outbred CD-1 mouse strain. Trypsinogens were
eluted under acidic conditions from the ecotin column and
immediately loaded onto a Mono S cation exchange column
equilibrated with 20 mM sodium acetate (pH 5.0). The Mono S
column was developed with a NaCl gradient, resulting in five
FIGURE 2. Identification of major trypsinogen isoforms expressed in the
mouse pancreas. A, chromatographic separation of trypsinogen isoforms.
Trypsinogens were purified from pancreas tissue extracts of CD-1mice using
ecotin affinity chromatography, and the ecotin eluate was loaded onto a
MonoS columnequilibratedwith 20mMsodiumacetate (pH5.0). The column
wasdevelopedwith a linear gradient of 0–0.5MNaCl. Peakswere analyzedby
SDS-PAGE, N-terminal sequencing, and mass spectrometry, as described
under “Experimental Procedures” and “Results.” B, two-dimensional PAGE of
a zymogen granule-enriched fraction of pancreas tissue from NMRI mice. Sil-
ver-stained spots were digested with trypsin and analyzed by peptide mass
fingerprinting, as described under “Experimental Procedures.” Spots for tryp-
sinogen isoforms T7, T8, T9, and T20, proelastase 3 (Ela3); chymotrypsinogen
B (Ctrb), and proelastase 1 (Ela1) are indicated.
FIGURE 3.Autoactivationofmouse trypsinogens. Trypsinogenswere incu-
bated at 2Mconcentrationwith 10nM initial trypsin in 0.1 M Tris-HCl (pH8.0),
1 mM CaCl2 (A) or 10 mM CaCl2 (B) and 0.05% Tween 20 at 37 °C. Aliquots (1.5
l) were withdrawn at the indicated times, and trypsin activity was deter-
mined as described under “Experimental Procedures.” Trypsin activity was
expressedaspercentageof themaximal activity determinedby full activation
with enteropeptidase. Representative experiments from four replicates are
shown.
TABLE 2
Relative expression levels ofmajor trypsinogen isoforms in themouse
pancreas determined by ion exchange chromatography (CD-1) or
two-dimensional gel electrophoresis (NMRI)
The averages from four experiments S.D. are indicated. See text for details.
Mouse strain
Relative expression levels (% of total)
T7 T8 T9 T20
CD-1 41 1 47 3 12 2
NMRI 25 1 33 1 27 1 15 2
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peaks (Fig. 2A). Edman degradation unambiguously identified
the small fourth peak as proelastase 3 (N terminus is CGQPS)
and the large fifth peak as the cationic T7 trypsinogen isoform,
which has a unique N-terminal sequence, LPLDD (Fig. 1). The
other three peaks proved to be trypsinogens but had the sameN
termini, FPVDD; therefore, these were subjected to in-gel tryp-
tic digestion followed by mass spectrometric nanosequencing,
which revealed the identity of the first peak as isoform T20 and
the second and third peaks as isoformsT9 andT8 (Fig. 2A). The
latter two isoforms are nearly identical in their amino acid
sequence (99% identity, Fig. 1) and MS/MS peptide coverage
did not include any regions thatwere distinctive.On the basis of
a slight difference in their ionic character, T9 was assigned to
the second peak and T8 to the third peak. N-terminal sequenc-
ing of the combined second/third peaks after activation of tryp-
sinogen to trypsin indicated a mixture of Val/Ile amino acids at
position 35 (IVGGYTCRENS(V/I)P), with a preponderance of
Val, confirming that the smaller second peak is T9 (containing
FIGURE 4. Effect of mouse Ctrc onmouse trypsinogen T7. A, autoactivation was measured in 1 and 10 mM CaCl2 in the absence (solid symbols) or presence
(open symbols) of 25 nMmouse Ctrc, as described under “Experimental Procedures.” B, SDS-PAGE analysis of the autoactivation reaction in 1mMCaCl2. Samples
were withdrawn at the indicated time points, precipitated with trichloroacetic acid, electrophoresed, and stained as described under “Experimental Proce-
dures.” C, cleavage of T7 trypsinogen by 25 nM mouse Ctrc. Incubations were performed with 2 M trypsinogen in 0.1 M Tris-HCl (pH 8.0) in the absence or
presence of 10 mM CaCl2. Samples were precipitated with trichloroacetic acid and analyzed by SDS-PAGE and Coomassie Blue staining. Representative
experiments from three replicates are shown. D, cleavage of the activation peptide of trypsinogen T7 by mouse Ctrc. Primary structure of the native T7
activation peptidewith proteolytic cleavage sites for Ctrc and trypsin is also indicated. Note that theN-terminal amino acid ofmature trypsinogen is Leu-16, as
the 15-amino acid-long secretory signal peptide is removed in the endoplasmic reticulum. Trypsinogen was incubated at 2M concentration with 25 nM Ctrc
in 0.1 M Tris-HCl (pH 8.0) and 0 or 10mMCaCl2 (final concentrations) at 37 °C. To prevent autoactivation, 25 nM human SPINK1 trypsin inhibitor was included. At
the indicated times, reactionswere terminated by precipitationwith trichloroacetic acid, and sampleswere analyzed by nonreducing SDS-PAGE and Coomas-
sie Blue staining. Relevant segments of representative gels (from two replicates) demonstrate the small mobility shift of the trypsinogen band caused by
Ctrc-mediated cleavageof the Leu-18–Asp-19peptidebond.Note that the rapid rateof cleavage is partly due to theaddedMet-Ala sequenceat theN terminus
of recombinant T7.
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Ile-35) and the larger third peak is T8 (containing Val-35) (see
Fig. 1). Both N-terminal sequencing (CGVPA) and MS/MS
indicated that the T9/T8 peaks were contaminated with some
Ctrb. Quantitative evaluation of trypsinogen peaks was per-
formed as described under “Experimental Procedures,” and the
following relative expression levels were obtained (mean 
S.D., n 4): 41 1% for T7; 47 3% for T8 and T9 combined,
and 12 2% for T20 (Table 2).
To confirm our findings with an independent method and in
a different mouse strain, we used a proteomic approach based
on two-dimensional PAGE, followed by in gel-digestion of sil-
ver-stained protein spots and peptide mass fingerprinting after
MALDI-TOF mass spectrometry. Fig. 2B demonstrates two-
dimensional PAGE protein patterns of a granule-enriched pan-
creas homogenate from the outbredNMRImouse strain. In the
20–37-kDa molecular mass range, the same four trypsinogen
isoforms were identified as with the chromatographic
approach. The relative proportions of spot intensities (mean
S.D., n 4) were 25 1% for T7, 33 1% for T8, 27 1% for
T9, and 15 2% for T20 (Table 2). These values compare fairly
well, within experimental error, with those obtained for CD-1
mice.
Autoactivation ofMouse Trypsinogens—Large scale purifica-
tion of different trypsinogen isoforms from themouse pancreas
is impractical, and preparations may be contaminated with low
levels of other pancreatic proteases. In contrast, recombinant
expression should provide highly purified homogeneous
enzyme preparations. We previously established methodology
for the expression and purification of human trypsinogens (15,
16), and here we used the same approach to obtain functionally
competent mouse trypsinogen preparations. Trypsinogens
were expressed in E. coli as inclusion bodies, renatured in vitro
and purified by ecotin-affinity chromatography. When mouse
trypsinogens were incubated in 1mMCaCl2 at pH 8.0, isoforms
T7, T8, and T9 autoactivated and reached about 40–60% of
potentially attainable trypsin levels, indicating that some
autocatalytic (trypsin-mediated) degradation occurred (Fig.
3A) during autoactivation. In contrast, T20 did not autoac-
tivate under these conditions. As expected, high concentra-
tions of calcium (10 mM) increased the rate of autoactivation
and stabilized trypsinogens against degradation, yielding
80–100% of attainable trypsin levels. The stimulatory effect
of calcium on the autoactivation of T20 was particularly
striking (Fig. 3B).
FIGURE 5. Effect of mutations p.L82A and p.L149A onmouse trypsinogen T7. A, autoactivation was measured in 1 mM CaCl2 as described under “Experi-
mental Procedures.” Trypsin activity was expressed as percentage of the maximal activity determined by full activation with enteropeptidase. B, cleavage of
wild-type and p.L82A T7 trypsinogen by 25 nM mouse Ctrc. C, cleavage of wild-type and p.L149A T7 trypsinogen by 25 nM mouse Ctrc. Incubations were
performed with 2 M trypsinogen in 0.1 M Tris-HCl (pH 8.0) in the absence of calcium. Trypsinogen samples were precipitated with trichloroacetic acid and
analyzed by SDS-PAGE and Coomassie Blue staining. Representative experiments from two replicates are shown.
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Effect of Mouse Ctrc on T7 Trypsinogen—Addition of 25 nM
mouse Ctrc to the autoactivation assays of isoform T7 moder-
ately (by 35%) reduced trypsin levels in 1 mM calcium and
slightly stimulated the rate of autoactivation in 10 mM calcium
(Fig. 4A). SDS-PAGE analysis of the autoactivation reaction in 1
mM calcium, in the absence of Ctrc, confirmed conversion of
the T7 trypsinogen band to trypsin and also indicated degrada-
tion fragments generated by cleavages of trypsin-sensitive pep-
tide bonds Arg-123–Val-124 and Lys-194–Asp-195 (Fig. 4B,
left panel, see also Fig. 1). These were identified by N-terminal
sequencing, similarity to the published degradation fragments
of rat anionic trypsinogen-2 (26), and comparison of the band-
ing pattern with that of the T7 p.R123H mutant (see below).
Note that because of an extra amino acid in the activation pep-
tide of T7, amino acid numbering is shifted by one relative to
human and other mouse trypsinogens (see Fig. 1). Cleavage
after Arg-123 should result in a fully active two-chain trypsin
(27, 28), whereas cleavage after Lys-194 causes inactivation (26,
29). Ctrc caused a small shift of the T7 trypsinogen band, sug-
gesting cleavage of the activation peptide (Fig. 4B, right panel).
In addition, the banding pattern of degradation fragments
becamemore complex, which is consistent with the lower tryp-
sin activity attained during autoactivation in 1 mM calcium in
the presence of Ctrc.
To identify Ctrc-mediated cleavages of trypsinogen, we per-
formed digestion experiments with short incubation times
when no trypsinogen activation took place and no trypsin activ-
ity was present. Under these conditions, slow cleavage of the
Leu-149–Ser-150 peptide bond in the autolysis loop was
observed in the absence of calcium (Fig. 4C, left panel), and this
was completely inhibited by 10 mM calcium (Fig. 4C, right
panel, see also Fig. 1). The Leu-82–Glu-83 peptide bond (cor-
responding to Leu-81–Glu-82 in human trypsinogens and
other studied mouse isoforms) in the calcium binding loop was
not cleaved to a detectable extent. This finding suggested that
in T7 the moderate degradation observed during autoactiva-
tion in 1 mM calcium in the presence of Ctrc is mediated by
cleavage of the Leu-149–Ser-150 peptide bond. To confirm this
assumption, we compared autoactivation of the T7 p.L82A and
p.L149A mutants in 1 mM calcium and found that only muta-
tion of p.L149A protected against degradation in the presence
of Ctrc (Fig. 5). Interestingly, mutant p.L82A suffered Ctrc-de-
pendent degradation during autoactivation to an even larger
extent than wild-type T7.
N-terminal Processing of T7 Trypsinogen by Mouse Ctrc—
Among the activation peptide sequences of mouse trypsino-
gens, only T7 contains a potentially Ctrc-sensitive peptide
bond, Leu-18–Asp-19 (Fig. 1). Inspection of Fig. 4B revealed
that the T7 trypsinogen band became slightly shifted as a result
of treatment with Ctrc, suggesting that the activation peptide
might be cleaved at Leu-18–Asp-19. When samples were run
under nonreducing conditions, the mobility shift caused by
N-terminal processing of the T7 activation peptide became
more apparent (Fig. 4D), andN-terminal sequencing confirmed
the predicted cleavage site. However, in contrast to human cat-
ionic trypsinogen, the rate of autoactivation of N-terminally
processed T7 was only negligibly stimulated (see Fig. 4A, right
panel), indicating that Ctrc does not regulate activation of
mouse trypsinogens through cleavage of the activation peptide.
Effect of the p.R123H Mutation on T7 Trypsinogen—Muta-
tion p.R123H protected T7 trypsinogen against degradation
during autoactivation in 1 mM calcium in the presence of Ctrc
(Fig. 6); however, it had no effect on the cleavage of the Leu-
149–Ser-150 peptide bond per se. This observation indicates
thatmoderate degradation ofT7 during autoactivation is due to
the combined effects of Ctrc-mediated and tryptic cleavages
after Leu-149 and Arg-123, respectively (see Fig. 1).
Effect of Mouse Ctrc on T8 and T9 Trypsinogen—Mouse Ctrc
almost completely inhibited autoactivation of T8 and T9 tryp-
sinogen in 1 mM calcium and markedly reduced it in 10 mM
calcium (Figs. 7 and 8). This inhibitory effect was not due to
degradation, as addition of enteropeptidase to the Ctrc-treated
samples resulted in the appearance of highly significant trypsin
activity. SDS-PAGE analysis of autoactivation in 1mM calcium,
FIGURE 6. Effect of mutation p.R123H on mouse trypsinogen T7. A, auto-
activation was measured in 1 mM CaCl2 as described under “Experimental
Procedures.” Trypsin activity was expressed as percentage of the maximal
activity determined by full activation with enteropeptidase. B, SDS-PAGE
analysis of the autoactivation reaction. Sampleswerewithdrawn at indicated
times, precipitated with trichloroacetic acid, electrophoresed, and stained as
described under “Experimental Procedures.” C, cleavage of wild-type and
p.R123H T7 trypsinogen by 25 nM mouse Ctrc. Incubations were performed
with 2 M trypsinogen in 0.1 M Tris-HCl (pH 8.0) in the absence of calcium.
Samples were precipitated with trichloroacetic acid and analyzed by SDS-
PAGE and Coomassie Blue staining. Cleavage products were identified with
N-terminal sequencing. Representative experiments from two replicates are
shown.
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in the absence of Ctrc, demonstrated conversion of trypsinogen
to trypsin with the characteristic degradation fragments gener-
ated by tryptic cleavage of the Arg-122–Val-123 and Lys-193–
Asp-194 peptide bonds (Figs. 7B and 8B, left panel, see also Fig.
1). In dramatic contrast, when autoactivation was followed in
the presence of Ctrc, no trypsin band nor any of the tryptic
degradation bands were observed. Instead, Ctrc rapidly and
completely cleaved T8 and T9 trypsinogen at a single site,
which N-terminal sequencing revealed as the Phe-150–Gly-
151 peptide bond (Figs. 7B and 8B, right panel). This peptide
bond lies within the so-called autolysis loop, a flexible segment
between residues 146 and 154 (Fig. 1).When cleavage of T8 and
T9 trypsinogen byCtrcwas studiedwith short incubation times
(i.e. before autoactivation occurred), both isoforms were pri-
marily cleaved at the Phe-150–Gly-151 peptide bond, with
minimal cleavage observed at the Leu-81–Glu-82 peptide bond
in the absence of calcium (Figs. 7C and 8C). Cleavage of the
Phe-150–Gly-151 peptide bond was slower but still readily
detectable in 10 mM calcium.
Cleavage of the Phe-150–Gly-151 Peptide Bond by Mouse
ChymotrypsinB (Ctrb)—Regulation of autoactivation of human
cationic trypsinogen by human CTRC is highly specific, and
other chymotrypsins and elastases do not cleave the CTRC
cleavage sites. To test whether the same Ctrc specificity exists
in the mouse, we compared the effect of mouse Ctrb and Ctrc
on T8 trypsinogen. As shown in Fig. 9A, autoactivation of T8
was much less effectively inhibited by 25 nM Ctrb than by an
equimolar concentration of Ctrc. In degradation experiments,
Ctrb cleaved the Phe-150–Gly-151 peptide bond at a more
than 7-fold slower rate than Ctrc (Fig. 9, B and C).
Effect of the p.R122H Mutation on T8 Trypsinogen—Muta-
tion p.R122H slightly stimulated autoactivation of T8 trypsin-
ogen in 1 mM calcium, in the absence of Ctrc (Fig. 10A). In the
presence of Ctrc, however, autoactivation was strongly inhib-
ited by Ctrc, approximately to the same extent as seen with
wild-type T8 (Fig. 10B, cf. Fig. 7A). Consistent with the robust
inhibitory effect, the Phe-150–Gly-151 peptide bond was
cleaved by Ctrc almost as well in T8 p.R122H trypsinogen as in
wild-type T8 (Fig. 10C).
Cleavage of the Autolysis Loop in the p.S150F Human Cati-
onic TrypsinogenMutant Inhibits Autoactivation—Themajor-
ity of mammalian trypsinogens do not contain Phe-150 in their
autolysis loop. To test whether introduction of Phe-150 would
reconstitute the chymotrypsin-dependent autoactivation inhi-
FIGURE 7. Effect of mouse Ctrc onmouse trypsinogen T8. A, autoactivation was measured in 1 and 10mM CaCl2, in the absence (solid symbols) or presence
(open symbols) of 25nMmouseCtrc, as describedunder “Experimental Procedures.”Where indicated, 2l of 1.4g/ml humanenteropeptidase (EP)was added.
B, SDS-PAGE analysis of the autoactivation reaction in 1mM CaCl2. Samples were withdrawn at indicated times, precipitated with trichloroacetic acid, electro-
phoresed, and stained as described under “Experimental Procedures.” C, cleavage of trypsinogen by 25 nMmouse Ctrc. Incubationswere performedwith 2M
trypsinogen in 0.1MTris-HCl (pH8.0) in the absenceor presenceof 10mMCaCl2. Sampleswereprecipitatedwith trichloroacetic acid andanalyzedbySDS-PAGE
and Coomassie Blue staining. Cleavage products were identified with N-terminal sequencing. In the absence of calcium (left panel), the faint bands above and
below themajor cleavageproducts correspond to fragments of trypsinogen cleaved at the Leu-81–Glu-82peptidebond. The faint band visible in thepresence
of 10 mM calcium (right panel) could not be identified. Representative experiments from three replicates are shown.
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bition in anothermammalian trypsinogen, wemutated Ser-150
in human cationic trypsinogen to Phe. Because human CTRC
cleaves the Leu-81–Glu-82 peptide bond and causes trypsino-
gen degradation, we used human CTRB2 to selectively cleave
the newly created Phe-150–Gly-151 peptide bond. CTRB2 at
25 nM concentration had no effect on the autoactivation of
wild-type cationic trypsinogen (Fig. 11A), but it inhibited acti-
vation of the p.S150F mutant (Fig. 11B), via cleavage at the
Phe-150–Gly-151 peptide bond (Fig. 11C).
Effect of Mouse Ctrc on T20 Trypsinogen—Finally, mouse
Ctrc had essentially no effect on trypsinogen T20, except for a
slight stimulation of the activation rate in 10 mM calcium (Fig.
12A). On SDS-PAGE, no trypsinogen to trypsin conversionwas
evident in 1mMcalcium, in the absence or presence ofCtrc (Fig.
12B). Note that T20 trypsinogen ran as a doublet on gels, which
seems to represent differently denatured conformers, as N-ter-
minal sequencing and mass spectrometry indicated molecular
homogeneity (data not shown). Finally, cleavage of T20 with
Ctrc resulted in very faint degradation bands even in the
absence of calcium, indicating that this isoform is resistant to
Ctrc (Fig. 12C).
DISCUSSION
The aim of this study was to identify the major trypsinogen
isoforms expressed by the mouse pancreas and characterize
their regulation of autoactivation bymouse Ctrc. These studies
were undertaken to clarify whether introduction of trypsinogen
mutations associated with human hereditary pancreatitis into
mouse trypsinogens would offer a viable approach to model
hereditary pancreatitis in mice. Previous attempts to generate
transgenicmice expressing the codingDNA for human cationic
trypsinogen with the p.R122H mutation failed to recapitulate
hereditary pancreatitis, partly because of the low transgene
expression levels (6). Introduction ofmutation p.R122H into an
endogenous mouse trypsinogen may circumvent the expres-
sion problem. However, the effect of p.R122H in human cat-
ionic trypsinogen is dependent on CTRC (3), and it has been
unknownwhether autoactivation ofmouse trypsinogens is reg-
ulated by mouse Ctrc in a manner that mimics the human
situation.
Using two independent biochemical approaches with two
commonly used outbredmouse strains, we found that only four
trypsinogen isoforms,T7,T8,T9 andT20, are expressed to high
levels (Table 2) in the mouse pancreas, even though the mouse
genome contains 20 trypsinogen genes, of which 11 are poten-
tially functional (Table 1 and Fig. 1). The cationic isoform T7
was recently deleted in the C57BL/6 strain, and judging from
the residual trypsinogen content the authors suggested that T7
contributes 60% of total mouse trypsinogens (12, 13). Here, we
obtained smaller values (41% in CD-1 and 25% in NMRI mice);
however, these differences seem to fall within experimental
error and may even represent strain-specific differences. It is
important to note that Prss1 (T16) and Prss3 (T11) (see Table
FIGURE 8. Effect of mouse Ctrc onmouse trypsinogen T9. See Fig. 7 for experimental details. EP, human enteropeptidase.
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1), the presumed orthologs of human cationic trypsinogen
(PRSS1) and mesotrypsinogen (PRSS3), are not expressed at
detectable levels, indicating that assignment of orthology by
database curators may be unreliable and even misleading to
investigators, as evidenced by a recent study where expression
ofmouse Prss1 was studied (30). Finally, we emphasize that our
data pertain to the resting, unstimulatedmouse pancreas, and it
is possible, even likely, that upon hormonal stimulation the
trypsinogen expression pattern may change, as shown previ-
ously for rat p23, the ortholog of mouse T4 and T5, which
becomes drastically up-regulated upon cerulein stimulation
(31). Marked up-regulation of T5 was observed in a knock-out
mouse strain deficient in interferon regulatory factor 2 (32).
Autoactivation of mouse trypsinogens T7, T8, and T9 was
comparable, whereas T20 autoactivated more slowly, particu-
larly in 1 mM calcium (see Fig. 3). Surprisingly, regulation of
autoactivation by mouse Ctrc was isoform-specific and mech-
anistically different from the actions of human CTRC on
human cationic trypsinogen. Whereas the human enzyme tar-
gets regulatory cleavage sites in the activation peptide and the
calcium binding loop of cationic trypsinogen, these proved to
be irrelevant in mouse trypsinogens. Thus, Ctrc-mediated
cleavage of the activation peptide was observed only with the
T7 isoform, however, this N-terminal processing had no signif-
icant effect on autoactivation. Cleavage of the Leu-81–Glu-82
peptide bond in the calcium binding loop (Leu-82–Glu-83 in
T7) was not detectable in T7 or T20, and minimal cleavage was
seen in T8 andT9. In contrast, isoformsT8 andT9were rapidly
cleaved at the Phe-150–Gly-151 peptide bond in the autolysis
loop, and this cleavage resulted in marked inhibition of autoac-
tivation. The Phe-150–Gly-151 peptide bond was also cleaved
by Ctrb at a 7-fold slower rate. However, considering that Ctrb
is the most abundant chymotrypsin in the pancreas, physiolog-
FIGURE9.EffectofmouseCtrbonmouse trypsinogenT8.A, autoactivation
wasmeasured in1mMCaCl2 asdescribedunder “Experimental Procedures” in
the absenceor presenceof 25nMmouseCtrb or Ctrc, as indicated.B, cleavage
of trypsinogen by 25 nM Ctrb and Ctrc was compared in the absence of cal-
cium, as described in Fig. 7C. Representative experiments from two replicates
are shown. C, disappearance of the intact trypsinogen band was quantitated
by densitometry, and data from two experiments were plotted. For clarity,
error barswere omitted; the error was within 10% of the mean.
FIGURE 10. Effect ofmutation p.R122Honmouse trypsinogen T8. A, auto-
activation of wild-type and p.R122Hmutant T8 trypsinogenwasmeasured in
1 mM CaCl2 as described under “Experimental Procedures.” B, effect of 25 nM
mouse Ctrc on the autoactivation of the p.R122Hmutant T8. Conditionswere
the sameas inA.C, cleavageofwild-type andp.R122Hmutant T8 trypsinogen
by 25 nMmouse Ctrc in the absence of calcium. Samples were incubated and
analyzed as described in Fig. 7C. Representative experiments from two repli-
cates are shown.
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ical regulation of activation ofT8 andT9maybe also dependent
onCtrb. IsoformT7was also cleaved in the autolysis loop, albeit
slowly and at a different peptide bond (Leu-149–Ser-150),
which resulted in moderate degradation during autoactivation.
Nevertheless, isoform T7 was clearly less sensitive to chymo-
tryptic regulation than human cationic trypsinogen or mouse
trypsinogens T8 and T9.
The lack of cleavage at the Leu-81–Glu-82 (Leu-82–Glu-83
in T7) peptide bond by Ctrc may be partly explained by differ-
ences in the amino acid sequence of the calcium binding loop
(see Fig. 1). Furthermore, as we learned from the recent crys-
tal structure of human CTRC, recognition of the calcium
binding loop is governed by long range electrostatic interac-
tions between the negatively charged substrate and positively
charged surface regions on CTRC (33). These macroscopic
electrostatic interactions are less favorable in themouse, due to
missing positively charged residues in Ctrc (Arg-80 and Arg-
240) and negatively charged residues inmouse trypsinogens T7
(Glu-32, Asp-156, and Glu-157) and T8, T9, and T20 (Glu-79
and Glu-157) (see Fig. 1).
The majority of mammalian trypsinogens do not contain
Phe-150, indicating that this novel mechanism of autoactiva-
tion regulation may be unique to rodents. Human meso-
trypsinogen contains Phe-150, and cleavage at this site by
humanCTRCwas demonstrated previously (5), suggesting that
activation ofmesotrypsinogenmay be under similar regulation.
Human anionic and cationic trypsinogens contain Ser at posi-
tion 150, but mutation S150F confers sensitivity to CTRB2-
mediated cleavage of the autolysis loop, which inhibits autoac-
tivation in a manner that is similar to the Ctrc-dependent
inhibition of T8 and T9 in the mouse. Crystal structures of
mouse trypsinogens are not available, and the autolysis loop in
structures of rat anionic trypsinogen is disordered and not vis-
ible. Therefore, we used a bovine trypsinogen structure to
model the potential effects of cleavage of the autolysis loop after
Phe-150. As shown in Fig. 13, the autolysis loopmay be in close
proximity to the trypsinogen activation peptide, at least judged
by the position of Val-25, the first visible residue of the other-
wise disorderedN-terminal segment. Cleavage of the Phe-150–
Gly-151 peptide bond should increase themobility of the autol-
ysis loop, which may directly interact with the activation
peptide thereby decreasing its accessibility. One possible inter-
action may occur between the positive charge of the newly cre-
ated N terminus in the autolysis loop and the negatively
charged tetra-Asp motif in the activation peptide.
The Ctrc-dependent inhibition of autoactivation of T8
and T9 trypsinogens may have evolved as a protective mecha-
nism to curtail unwanted trypsinogen activation in the pan-
creas. This is conceptually analogous to the regulation of
human trypsinogens by human CTRC even though mechanis-
tic details are dissimilar. Interestingly, we found that cleavage of
the Phe-150–Gly-151 peptide bond in T8 and T9 trypsinogens
also inhibits activation by enteropeptidase, the physiological
trypsinogen activator in the duodenum (data not shown).
Although inhibition of digestive enzyme activation in the gut
may seemcounterintuitive, this chymotrypsin-dependent feed-
backmechanism likely ensures that intestinal trypsinogen acti-
vation proceeds with a slower, more prolonged kinetics, which
may be favorable for food digestion.
Intra-acinar cell activation of trypsinogen in cytoplasmic
vesicles of autophagic origin is an early event in experimental
models of acute pancreatitis (34). Genetic deletion of T7 was
recently shown to abolish intra-acinar trypsinogen activation in
response to hyperstimulation with cerulein: a somewhat per-
plexing observation as other trypsinogen isoforms could have
potentially be activated (12, 13). The results presented here
offer a plausible explanation for this puzzle. When trypsinogen
activation occurs, isoforms T8 and T9 may be inhibited in a
Ctrc or Ctrb-dependent manner, whereas T7 is less sensitive to
chymotryptic regulation. Because of its lower concentration
and poor activation, isoform T20 is unlikely to contribute to
intra-acinar trypsinogen activation to a detectable extent.
Finally, our data argue that in the context of mouse trypsino-
gens, human pancreatitis-associated mutations may not reca-
pitulate the pathogenic biochemical phenotype observed with
FIGURE11.Effect of humanCTRB2on theautoactivationofwild-typeand
p.S150F mutant human cationic trypsinogen (Hu1). A and B, autoactiva-
tionwasmeasured in 1mMCaCl2, in the absence or presence of 25 nM CTRB2,
as described under “Experimental Procedures.” C, cleavage of wild-type and
p.S150F mutant human cationic trypsinogen by 25 nM CTRB2 in the absence
of calcium. Incubationswere performed, and sampleswere analyzed as given
in Fig. 7C. To prevent autoactivation, 25 nM human SPINK1 trypsin inhibitor
was included. Representative experiments from two replicates are shown.
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human cationic trypsinogen.We found thatmutation p.R122H
did not affect inhibition of autoactivation by Ctrc in T8 trypsin-
ogen, which stands in contrast to the robust negative effect of
this mutation on CTRC-dependent degradation of human
cationic trypsinogen (3). Thus, introduction of humanmuta-
tions into mouse trypsinogens may not be a practical
approach for the generation of mouse models of human
hereditary pancreatitis.
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